Desvenlafaxine
Other / unclassified targets SLC6A2, SLC6A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed depressive disorder 1 milestone | |||||
| Filed | China (NMPA) | — | depressive disorder | — | “In January, the application for marketing approval of desvenlafaxine succinate extended-release tablets (indication: adult depression) in China was submitted” irasia.com ↗ “In January 2022, application for marketing approval of desvenlafaxine extended-release tablets for the treatment of depression was submitted” irasia.com ↗ “Application for marketing approval of desvenlafaxine succinate extended-release tablets in China was submitted” irasia.com ↗ |
| Approved Indication not stated 2 milestones | |||||
| Label expansions (2) | US (FDA) | PRISTIQ | — | 2013-02-14 – 2018-02-06 | fda.gov ↗ |
| Approved | US (FDA) | PRISTIQ | — | 2008-02-29 | fda.gov ↗ |
Trials 69 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT03733574 | Jun → Jul 2018 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03357796 | Nov → Dec 2017 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02054299 | Apr 2013 → Feb 2016 | — | University Medical Center Goettingen | Completed | No outcome recorded |
| Phase 1 | NCT01443208 | Nov → Dec 2011 | major depressive disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01101152 | Apr 2010 → Dec 2011 | — | University of Ottawa | Unknown | No outcome recorded |
| Phase 1 | NCT00818155 | Jan → Feb 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00440427 | Feb 2007 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00456898 | Jan → Mar 2007 | diabetic neuropathy, fibromyalgia, major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00397176 | Nov 2006 → Feb 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT04437485 | Oct 2020 → Aug 2022 | dysthymic disorder, major depressive disorder, prediabetes syndrome, type 2 diabetes mellitus | Indiana University | Completed | Missed primary |
| Phase 2 | NCT00696787 | Jun 2008 → Jan 2009 | fibromyalgia | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | Missed primary |
| Phase 2 | NCT00669110 | May 2008 → May 2010 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00619619 | Feb 2008 → Nov 2009 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT01977378 | Oct 2013 → Sep 2014 | major depressive disorder | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT00767624 | Dec 2008 → Jun 2015 | major depressive disorder, sleep disorder, initiating and maintaining sleep | Stanford University | Completed | Mixed |
| Phase 2/3 | NCT00301431 | Aug 2006 → Jun 2007 | fibromyalgia | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 2/3 | NCT00424892 | ? → Jun 2007 | fibromyalgia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 332 trials · 6 met primary · 6 missed | ||||||
| Phase 3 | NCT04364997 | Jun 2020 → Sep 2021 | major depressive disorder | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04345471 | May 2020 → Jul 2022 | major depressive disorder | Mochida Pharmaceutical Company, Ltd. | Completed | Missed primary |
| Phase 3 | NCT01371708 | Feb 2012 → Apr 2016 | major depressive disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01371721 | Feb 2012 → Oct 2015 | major depressive disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01372150 | Nov 2011 → Mar 2015 | major depressive disorder | Pfizer | Completed | Missed primary |
| Phase 3 | NCT01371734 | Aug 2011 → Sep 2015 | major depressive disorder | Pfizer | Completed | Missed primary |
| Phase 3 | NCT01527786 | Nov 2010 → Feb 2014 | depressive disorder | BC Women's Hospital & Health Centre | Completed | No outcome recorded |
| Phase 3 | NCT00888862 | Jun 2009 → Jun 2012 | major depressive disorder | Hamilton Health Sciences Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT00887224 | Jun 2009 → Mar 2011 | major depressive disorder | Pfizer | Completed | Met primary |
| Phase 3 | NCT00863798 | Apr 2009 → Mar 2010 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Missed primary |
| Phase 3 | NCT00831415 | Mar 2009 → Mar 2011 | major depressive disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00798707 | Dec 2008 → Apr 2010 | major depressive disorder | Pfizer | Completed | Met primary |
| Phase 3 | NCT00683800 | Jun 2008 → May 2010 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT00445679 | Jul 2007 → Feb 2009 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00384033 | Sep 2006 → Sep 2007 | major depressive disorder | Pfizer | Completed | Missed primary |
| Phase 3 | NCT00366652 | Sep 2006 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00369343 | Sep 2006 → Nov 2007 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Met primary |
| Phase 3 | NCT01050218 | Jul 2006 → Jan 2009 | diabetic polyneuropathy | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00369434 | Jun 2006 → Feb 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00329186 | May 2006 → Jun 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00329147 | May → Jun 2006 | depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00300378 | Mar 2006 → Jan 2007 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00283842 | Mar 2006 → Jun 2008 | diabetic neuropathy | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | Met primary Stop: Business |
| Phase 3 | NCT00195546 | Apr 2005 → Jan 2006 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00256685 | Sep 2004 → Jul 2005 | sleep disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00452595 | Jan 2004 → May 2005 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00421031 | Dec 2003 → Apr 2004 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Met primary |
| Phase 3 | NCT01309542 | Aug 2003 → Mar 2006 | major depressive disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00072774 | ? → Nov 2004 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00087737 | ? → May 2005 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00063206 | ? → May 2004 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Missed primary |
| Phase 3 | NCT00090649 | ? → Mar 2005 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 415 trials · 4 met primary · 1 missed | ||||||
| Phase 4 | NCT07795593 | Oct 2026 → May 2031 expected | diabetic kidney disease, diabetic neuropathy | University of Michigan | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02819921 | Nov 2017 → Mar 2019 | breast cancer | Seoul National University Hospital | Terminated | Met primary Stop: Enrollment |
| Phase 4 | NCT02330679 | Dec 2014 → Dec 2016 | major depressive disorder | University of Calgary | Unknown | No outcome recorded |
| Phase 4 | NCT02200406 | Jul 2014 → Jan 2017 | depressive disorder, opiate dependence | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 4 | NCT01974934 | Dec 2013 → Apr 2016 | cerebrovascular disorder | Hotel-Dieu Grace Healthcare | Unknown | No outcome recorded |
| Phase 4 | NCT01916824 | Aug 2013 → Dec 2015 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01975480 | Jan 2013 → Apr 2020 | generalized anxiety disorder | START Clinic for Mood and Anxiety Disorders | Completed | No outcome recorded |
| Phase 4 | NCT01537068 | Feb 2012 → Aug 2016 | dysthymic disorder | New York State Psychiatric Institute | Completed | Missed primary |
| Phase 4 | NCT01492621 | Nov 2011 → Sep 2013 | major depressive disorder | Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal | Unknown | No outcome recorded |
| Phase 4 | NCT01432457 | Oct 2011 → Jul 2012 | major depressive disorder | Pfizer | Completed | Met primary |
| Phase 4 | NCT01316302 | Apr 2011 → Nov 2012 | social phobia | The Medical Research Network | Completed | No outcome recorded |
| Phase 4 | NCT01188668 | Aug → Oct 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01189500 | Aug → Oct 2010 | — | Pfizer | Completed | Met primary |
| Phase 4 | NCT01121484 | Jun 2010 → Jun 2011 | major depressive disorder | Pfizer | Completed | Met primary |
| Phase 4 | NCT00952653 | Jun → Aug 2010 | major depressive disorder | Pfizer | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07385755 | Jan 2026 → Jan 2028 expected | migraine disorder | Tongji Hospital | Active not recruiting | No outcome recorded |
| — | NCT07361809 | Dec 2025 → Sep 2027 expected | herpes zoster | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07359248 | Dec 2025 → Dec 2027 expected | — | Tongji Hospital | Active not recruiting | No outcome recorded |
| — | NCT07171320 | Sep 2025 → Jun 2027 expected | fibromyalgia | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT01948895 | Aug 2012 → Jun 2014 | dysthymic disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Comparator or background therapy19 trials | ||||||
| Phase 1 | NCT02988024 Comparator | Dec 2016 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02055300 Comparator | Feb → Aug 2014 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00727064 Comparator | Jun → Aug 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT03321526 Background | Dec 2017 → Jun 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 2 | NCT00797966 Background | May 2009 → Jun 2010 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | Met primary |
| Phase 2/3 | NCT01803711 Background | Feb 2013 → Jun 2016 | cancer, cardiovascular disorder, diabetes mellitus, major depressive disorder | UConn Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04476030 Background | Nov 2020 → Oct 2021 | major depressive disorder | Biogen | Completed | Met primary |
| Phase 3 | NCT02400346 Background | Mar 2015 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01838876 Background | Apr 2013 → Jul 2015 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01715805 Background | Nov 2012 → Jun 2016 | major depressive disorder | Forest Laboratories | Completed | Missed primary |
| Phase 3 | NCT00824291 Comparator | Feb → Oct 2009 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00406640 Comparator | Dec 2006 → Feb 2008 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00401245 Comparator | Dec 2006 → Jan 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT05273996 Background | Sep 2021 → Apr 2027 expected | major depressive disorder, neurotic disorder | David Steffens | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04448431 Comparator | Jun 2020 → Jan 2022 | major depressive disorder | H. Lundbeck A/S | Completed | Met primary |
| Phase 4 | NCT02859103 Comparator | Jun 2017 → Nov 2019 | atypical depressive disorder, depressive disorder | Unity Health Toronto | Completed | No outcome recorded |
| Phase 4 | NCT01056289 Comparator | Mar 2010 → Feb 2011 | major depressive disorder | Pfizer | Completed | No outcome recorded |
| — | NCT06270433 Comparator | Feb → Dec 2024 | atypical depressive disorder | Jiangsu Province Nanjing Brain Hospital | Unknown | No outcome recorded |
| — | NCT01468610 Comparator | Jan 2012 → Sep 2014 | major depressive disorder | University of British Columbia | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-07-04 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - DESVENLAFAXINE SUCCINATE EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗
The Product, a Class 3 chemical drug, is the first generic drug of its kind that has been approved in China, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs. |
| 2022-08-26 | Lupin Limited | Regulatory Lupin Launches Desvenlafaxine Extended-Release Tablets in the United States lupin.com ↗
Mumbai, Baltimore, August 26, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of Desvenlafaxine Extended-Release Tablets, 25 mg, having received an approval from the United States Food and Drug Administration (FDA). |
| 2022-04-14 | Lupin Limited | Regulatory Lupin Receives Approval from U.S. FDA for Desvenlafaxine Extended-Release Tablets 25 mg lupin.com ↗
it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Desvenlafaxine Extended-Release Tablets, 25 mg |
| 2015-06-11 | Pfizer | Results Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder pfizer.com ↗
The study did not meet its primary objective to demonstrate superior efficacy of desvenlafaxine succinate sustained-release formulation compared to placebo. |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-07-04 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - DESVENLAFAXINE SUCCINATE EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL irasia.com ↗ |
| 2022-08-26 | Lupin Limited | Lupin Launches Desvenlafaxine Extended-Release Tablets in the United States lupin.com ↗ |
| 2022-04-14 | Lupin Limited | Lupin Receives Approval from U.S. FDA for Desvenlafaxine Extended-Release Tablets 25 mg lupin.com ↗ |
| 2017-03-02 | Lupin Limited | Lupin Launches Generic Pristiq® Tablets in the US lupin.com ↗ |
| 2017-03-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Pristiq® in the United States tevapharm.com ↗ |
| 2015-06-11 | Pfizer | Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder pfizer.com ↗ |
| 2009-03-19 | Impax Laboratories, LLC | Impax Pharmaceuticals to Co-Promote Wyeth's Pristiq(R) amneal.com ↗ |
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 101 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Desvenlafaxine | “ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876 ↗75“Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine,...” NCT02400346 ↗ “This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with...” NCT01371708 ↗ “We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight.” NCT04437485 ↗ “ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.” NCT01715805 ↗ “Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy” NCT03321526 ↗ “OBJECTIVE: To compare efficacy and safety of desvenlafaxine succinate (desvenlafaxine) with placebo for the treatment of vasomotor symptoms.” PMID 18165395 ↗ Jan 2008 “the serotonin-norepinephrine reuptake inhibitor desvenlafaxine in adults with painful diabetic peripheral neuropathy (DPN)” PMID 25018648 ↗ Jun 2014 “Desvenlafaxine significantly improved symptoms of depression versus placebo regardless of baseline BMI.” PMID 26644956 ↗ Jun 2015 “Serotonin-Norepinephrine Reuptake Inhibitors (SNRI's): Duloxetine, Venlafaxine, Desvenlafaxine” NCT07795593 ↗ “which included escitalopram, sertraline, and desvenlafaxine in a prescribed sequence.” PMID 27788313 ↗ Oct 2016 |
| Known as | D-veniz | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | DESV | “Desvenlafaxine (DESV) is a SNRI with minimal cardiotoxicity and drug interactions.” PMID 29738425 ↗ Sep 2018 |
| Known as | Desvenlafaxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | DESVENLAFAXINE FUMARATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Desvenlafaxine fumarate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Desvenlafaxine SR | “Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.” NCT01188668 ↗ |
| Known as | desvenlafaxine succinate | “The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo...” NCT00369434 ↗19“In an effort to establish the lowest effective dose of desvenlafaxine (administered as desvenlafaxine succinate), we assessed the efficacy, safety, and tolerability of 10- and...” PMID 23517291 ↗ Mar 2013 “The aim of this study was to evaluate open-label desvenlafaxine treatment (administered as desvenlafaxine succinate) in postmenopausal women who did not achieve clinical...” PMID 21323394 ↗ Mar 2011 “The primary objective was to evaluate the long-term safety of desvenlafaxine (administered as desvenlafaxine succinate) during open-label treatment in adult outpatients with a...” PMID 21977353 ↗ 2011 “OBJECTIVE: A previous trial of the serotonin-norepinephrine reuptake inhibitor desvenlafaxine (administered as desvenlafaxine succinate) raised concerns on potential serious...” PMID 23266840 ↗ Jan 2013 “The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are...” NCT00256685 ↗ “Study Comparing Discontinuation Symptoms in subjects with Major Depressive Disorder treated for 24 Weeks with Open-label 50 mg Desvenlafaxine Succinate Sustained-Release...” NCT01056289 ↗ “BACKGROUND: This study evaluated the efficacy and safety of low-dose desvenlafaxine (administered as desvenlafaxine succinate) in treating major depressive disorder (MDD).” PMID 23334675 ↗ Jan 2013 “This randomized, double-blind, placebo-controlled trial evaluated the short-term efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate)” PMID 20797382 ↗ Aug 2010 “Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.” NCT04364997 ↗ “OBJECTIVE: To compare efficacy and safety of desvenlafaxine succinate (desvenlafaxine) with placebo for the treatment of vasomotor symptoms.” PMID 18165395 ↗ Jan 2008 |
| Known as | Desvenlafaxine succinate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Desvenlafaxine succinate hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Desvenlafaxine succinate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Desvenlafaxine Succinate Sustained-Release | “A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of...” NCT01121484 ↗4“This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained...” NCT00824291 ↗ “This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with...” NCT01371708 ↗ “The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with...” NCT00424892 ↗ “Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)” NCT01432457 ↗ |
| Known as | Desvenlafaxine Succinate Sustained-Release Tablets | “Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)” NCT00619619 ↗ |
| Known as | Desvenlafaxine, Pristiq | “Desvenlafaxine, Pristiq” NCT01916824 ↗ |
| Known as | DVLX | “We report a study of the serotonin-norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (DVLX) for PDD.” PMID 30423468 ↗ Nov 2018 |
| Known as | DVS | “The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of...” NCT00683800 ↗3“The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are...” NCT00256685 ↗ “Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).” NCT00369343 ↗ “Desvenlafaxine succinate (DVS) has been developed for the treatment of MDD.” NCT00888862 ↗ |
| Known as | Dvs anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | DVS SR | “The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo...” NCT00369434 ↗23“A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of...” NCT01121484 ↗ “An Open-Label, Two-Period, Sequential Drug Interaction Study to Evaluate the Effect of Multiple Doses of Desvenlafaxine Succinate Sustained Release (DVS SR) on the...” NCT00952653 ↗ “This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained...” NCT00824291 ↗ “This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with...” NCT01371708 ↗ “This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major...” NCT01371734 ↗ “This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major...” NCT01372150 ↗ “Study Comparing Discontinuation Symptoms in subjects with Major Depressive Disorder treated for 24 Weeks with Open-label 50 mg Desvenlafaxine Succinate Sustained-Release...” NCT01056289 ↗ “The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with...” NCT00424892 ↗ “A Randomized, Open-Label, Cross-Over Drug Interaction Study to Evaluate the Effects of Desvenlafaxine (DVS SR) and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects” NCT00329147 ↗ “Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)” NCT01432457 ↗ |
| Known as | DVS-233 | “DVS-233 SR (desvenlafaxine sustained release )” NCT00452595 ↗ |
| Known as | DVS-233 SR | “The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of...” NCT00421031 ↗ |
| Known as | Khedezla | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Mdd-xr | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Newven | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | O-desmethyl venlafaxine succinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | O-desmethylvenlafaxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | O-desmethylvenlafaxine (odv) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | O-desmethylvenlafaxine fumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Pristiq | “Desvenlafaxine (Pristiq)” NCT00797966 ↗ |
| Known as | WY-45233 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Action | Inhibit | “the serotonin-norepinephrine re-uptake inhibitor desvenlafaxine” PMID 25758058 ↗ Mar 2015 |
| Modality | Other / unclassified | “the serotonin-norepinephrine reuptake inhibitor (SNRI) desvenlafaxine” PMID 30423468 ↗ Nov 2018 |
| Route | Oral | “4 Fixed Oral Doses” NCT00283842 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter inhibitor” CHEMBL1118 ↗ |
| Target | SLC6A4 | “Serotonin transporter inhibitor” CHEMBL1118 ↗ |